Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphe nuclei.
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001519:Behavior / Q000187:drug effects*; D002421:Caudate Nucleus / Q000502:physiology; D003533:Cyproheptadine / Q000494:pharmacology; D003913:Dextroamphetamine / Q000494:pharmacology; D003988:Dibenzothiepins / Q000494:pharmacology; D004149:Dioxoles / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008636:Mesencephalon / Q000502:physiology*; D008774:Methylphenidate / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011699:Putamen / Q000502:physiology; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013238:Stereotaxic Techniques; D013239:Stereotyped Behavior / Q000187:drug effects*; D013268:Stimulation, Chemical; D013378:Substantia Nigra / Q000502:physiology; D013440:Sulfides / Q000494:pharmacology; D013997:Time Factors
D003988:Dibenzothiepins; D004149:Dioxoles; D010879:Piperazines; D011743:Pyrimidines; D013440:Sulfides; D008774:Methylphenidate; D003533:Cyproheptadine; D001285:Atropine; D000661:Amphetamine; D006220:Haloperidol; D001058:Apomorphine; D003913:Dextroamphetamine; D004298:Dopamine